{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137043680706944.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1872-034x.2007.00094.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1872-034X.2007.00094.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1872-034X.2007.00094.x"}},{"identifier":{"@type":"PMID","@value":"17584261"}}],"dc:title":[{"@value":"Low serum level of hepatitis B core‐related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p><jats:bold>Aim: </jats:bold> The clinical significance of hepatitis B virus (HBV) core‐related antigen (HBcrAg) in predicting the reactivation of hepatitis after halting lamivudine administration was analyzed.</jats:p><jats:p><jats:bold>Methods: </jats:bold> A total of 34 patients with chronic hepatitis B were enrolled. Lamivudine was administered for at least 6 months before cessation, and reactivation of hepatitis was defined as elevation of alanine aminotransferase levels to more than 80 IU/L within 12 months of cessation.</jats:p><jats:p><jats:bold>Results: </jats:bold> In total, 20 (59%) patients experienced hepatitis reactivation. Although concentrations of HBV DNA and HBcrAg in serum did not differ between the two groups of patients at the onset of lamivudine administration, HBcrAg serum levels were significantly higher (<jats:italic>P </jats:italic>=<jats:italic> </jats:italic>0.009) in the reactivation patients (median 4.9, 25–75% range 4.7– 5.9 log unit/mL) than the non‐reactivation patients (median 3.2, 25–75% range <3.0–4.5 log unit/mL) post‐lamivudine treatment. The concentration of HBV DNA did not differ between the two groups (median <3.7, 25–75% range <3.7–<3.7 log copy/mL in the reactivation group vs. median <3.7, 25–75% range <3.7–<3.7 log copy/mL in the non‐ reactivation group). Receiver operating characteristic analysis of HBcrAg concentration showed an area under the curve of 0.764 in predicting patients without reactivation of hepatitis.</jats:p><jats:p><jats:bold>Conclusion: </jats:bold> HBcrAg can be a useful marker to identify patients who are not at risk of reactivation of severe hepatitis after discontinuation of lamivudine administration.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137043680706830","@type":"Researcher","foaf:name":[{"@value":"Akihiro Matsumoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706816","@type":"Researcher","foaf:name":[{"@value":"Eiji Tanaka"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706820","@type":"Researcher","foaf:name":[{"@value":"Masahito Minami"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706822","@type":"Researcher","foaf:name":[{"@value":"Takeshi Okanoue"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706825","@type":"Researcher","foaf:name":[{"@value":"Hiroshi Yatsuhashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706826","@type":"Researcher","foaf:name":[{"@value":"Shinya Nagaoka"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706821","@type":"Researcher","foaf:name":[{"@value":"Fumitaka Suzuki"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706827","@type":"Researcher","foaf:name":[{"@value":"Mariko Kobayashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706818","@type":"Researcher","foaf:name":[{"@value":"Kazuaki Chayama"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706945","@type":"Researcher","foaf:name":[{"@value":"Michio Imamura"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706829","@type":"Researcher","foaf:name":[{"@value":"Hiroshi Yotsuyanagi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706944","@type":"Researcher","foaf:name":[{"@value":"Shigeru Nakaoka"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706819","@type":"Researcher","foaf:name":[{"@value":"Noboru Maki"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706828","@type":"Researcher","foaf:name":[{"@value":"Sumio Kawata"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706823","@type":"Researcher","foaf:name":[{"@value":"Hiromitsu Kumada"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706817","@type":"Researcher","foaf:name":[{"@value":"Shiro Iino"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043680706824","@type":"Researcher","foaf:name":[{"@value":"Kendo Kiyosawa"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13866346"},{"@type":"EISSN","@value":"1872034X"}],"prism:publicationName":[{"@value":"Hepatology Research"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2007-06-18","prism:volume":"37","prism:number":"8","prism:startingPage":"661","prism:endingPage":"666"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1872-034X.2007.00094.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1872-034X.2007.00094.x"}],"createdAt":"2007-06-19","modifiedAt":"2023-10-11","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004235524254208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Characteristics and prediction of hepatitis <scp>B</scp> e‐antigen negative hepatitis following seroconversion in patients with chronic hepatitis <scp>B</scp>"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235525732352","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus (HBV)‐infected patients with low hepatitis B surface antigen and high hepatitis B core‐related antigen titers have a high risk of HBV‐related hepatocellular carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013168820559232","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693322536960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum hepatitis B core‐related antigen as a treatment predictor of pegylated interferon in patients with <scp>HB</scp>eAg‐positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710756364160","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus core‐related antigen levels predict progression to liver cirrhosis in hepatitis B carriers"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302866851404928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565165280107648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181214789888","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584343749915776","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Kinetics of serum O‐glycosylated M‐hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660687481088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660687497728","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Treatment of chronic hepatitis B with nucleos(t)ide analogues"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660687642496","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Anti‐hepatitis B virus therapy: To stop, or not to stop: Has the question been solved?"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204793861376","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Guidelines for avoiding risks resulting from discontinuation of nucleos(t)ide analogues in patients with chronic hepatitis B (2012)"},{"@language":"ja","@value":"核酸アナログ薬中止に伴うリスク回避のための指針2012―厚生労働省「B型肝炎の核酸アナログ薬治療における治療中止基準の作成と治療中止を目指したインターフェロン治療の有用性に関する研究」の報告―"},{"@language":"ja-Kana","@value":"カクサン アナログヤク チュウシ ニ トモナウ リスク カイヒ ノ タメ ノ シシン 2012 : コウセイ ロウドウショウ 「 Bガタ カンエン ノ カクサン アナログヤク チリョウ ニ オケル チリョウ チュウシ キジュン ノ サクセイ ト チリョウ チュウシ オ メザシタ インターフェロン チリョウ ノ ユウヨウセイ ニ カンスル ケンキュウ 」 ノ ホウコク"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204795595008","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The evaluation of the sensitivity between serum and plasma specimen for COBAS TaqMan HBV v2.0"},{"@language":"ja","@value":"コバスＴａｑＭａｎ　ＨＢＶ「オート」ｖ２．０における同一時の血清検体と血漿検体のＨＢＶ　ＤＮＡ検出率の検討"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679769342720","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Evaluation of hepatitis B patients under treatment with nucleoside analogues by COBAS TaqMan HBV Test"},{"@language":"ja","@value":"抗ウイルス治療中のＢ型慢性肝炎における血中ＨＢＶ－ＤＮＡの評価～コバスＴａｑＭａｎ　ＨＢＶ「オート」による検討"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679770184960","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Three cases of chronic hepatitis B in that interferon therapy was indicated"},{"@value":"インターフェロン治療を行ったB型慢性肝炎の3例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク インターフェロン チリョウ オ オコナッタ Bガタ マンセイ カンエン ノ 3レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771191808","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The role of hepatitis B virus core-related antigen for predicting the incidence of HCC"},{"@language":"ja","@value":"ＨＢＶ関連肝細胞癌サーベイランスにおけるＨＢコア関連抗原の有用性"},{"@language":"ja-Kana","@value":"HBV カンレン カン サイボウガン サーベイランス ニ オケル HB コア カンレン コウゲン ノ ユウヨウセイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2007.00094.x"},{"@type":"OPENAIRE","@value":"doi_dedup___::38eed04679a1436be8192bde2612a2bd"},{"@type":"CROSSREF","@value":"10.1111/hepr.12208_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.1111/hepr.13277_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.2957/kanzo.49.483_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.3390/ijms222011051_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.1111/jvh.13869_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.1111/liv.13046_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.1111/jgh.13989_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.853_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.237_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.3350/cmh.2022.0434_references_DOI_3eEnnDFUT4OqPhnDIV62rlKjtRE"},{"@type":"CROSSREF","@value":"10.1007/s00535-017-1386-2_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.1007/s00535-017-1360-z_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.2957/kanzo.52.387_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.2957/kanzo.52.756_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2011.00910.x_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2011.00921.x_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2012.01001.x_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_5mrHCvnZILBEuFfuS4aUXsrvfWu"}]}